AI-enabled drug discovery reaches clinical milestone.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

6 citing papers in PubMed.

1. Target identification and assessment in the era of AI.Nature reviews. Drug discovery · 2026
   Review
2. Reimagining human-centric drug development with new approach methodologies.Science (New York, N.Y.) · 2026
   Review
3. In Silico Drug Design and Discovery: Big Data for Small Molecule Design-2nd Edition.Biomolecules · 2026
   Article
4. Artificial Intelligence and Machine Learning Applications in Fibromuscular Dysplasia: Transforming Diagnosis, Risk Stratification, and Clinical Decision-Making.Journal of cardiovascular translational research · 2026
   Review
5. Recent advances in the pharmacology of voltage-gated ion channels.Pharmacological reviews · 2025
   Review
6. Integrative structural profiling and ligand optimisation across the transthyretin mutational landscape.NPJ systems biology and applications · 2025
   Article

Corrections and comments

• Erratum issued
  Publisher Correction: AI-enabled drug discovery reaches clinical milestone.2025

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.